SZLS — StageZero Life Sciences Income Statement
0.000.00%
HealthcareAdventurousMicro Cap
Annual income statement for StageZero Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.186 | 0.139 | 4.15 | 5.07 | 3.8 |
Cost of Revenue | |||||
Gross Profit | -0.906 | -0.928 | 0.696 | 1.18 | -0.404 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 4.69 | 5.06 | 11 | 12.6 | 15.2 |
Operating Profit | -4.51 | -4.92 | -6.86 | -7.48 | -11.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.69 | -3.48 | -6.86 | -7.48 | -11.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -3.69 | -3.48 | -6.86 | -7.48 | -11.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -3.69 | -3.48 | -6.86 | -7.48 | -11.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.69 | -3.48 | -6.86 | -7.48 | -11.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.216 | -0.131 | -0.153 | -0.088 | -0.038 |